Soft Tissue Image by KA Imaging’s Reveal 35C Undercovers Mass Behind In-Dwelling Device
27.2.2023 10:05:00 EET | Business Wire | Press release
Manufacturer KA Imaging announced a study examining “single-exposure dual-energy radiography for the subtraction of in-dwelling devices in the soft tissue image” that made use of the Reveal 35C X-ray detector, powered by Spectral DR™ technology.
Using the Reveal 35C detector, the purpose of the study was to determine the clinical value of removal of in-dwelling devices in the dual-energy soft tissue X-ray image. According to the study, the spectral radiographic images revealed a suspicious soft tissue mass in one of the cases by subtraction of an overlapping pacemaker in the soft tissue image1.
Images were taken from 23 patients having at least one in-dwelling device, and the patients were all part of an on-going 600 patient study using the Reveal 35C detector at Taipei Medical University Hospital in Taiwan.
“The fact that the soft tissue image was able to find the mass, not seen in the conventional DR image, overlapping a pacemaker is quite promising and indicates that Spectral DR™ technology can efficiently subtract, in addition to bone calcium, higher atomic number materials such as metals associated with the pacemaker,” said Dr. Karim S. Karim, CTO of KA Imaging. “Spectral radiographic images generated by Spectral DR™ can play an important role in early disease detection for better outcomes,” says Amol Karnick, President and CEO.
The study will be presented at this year’s European Congress of Radiology (ECR). In addition to the e-poster at the scientific congress, KA Imaging is part of the technical exhibition at Expo X4, booth 437.
ECR is one of the largest medical meetings in Europe and the second-largest radiological meeting in the world.
Spectral DR™ technology enables dual-energy subtraction, providing bone and tissue differentiation with a single standard X-ray exposure. It acquires three images simultaneously (DR, bone and soft tissue dual-energy X-ray images). The technology mimics the workflow, dose and techniques of state-of-the-art mobile DR X-ray detectors.
About KA Imaging
A spin-off from the University of Waterloo, KA Imaging specializes in developing innovative X-ray imaging technologies and systems, providing solutions to the medical, veterinary, and non-destructive test industrial markets.
1. P-C. Chou, K. S. Karim. “Single-exposure dual-energy radiography for the subtraction of in-dwelling devices in the soft tissue image”. European Congress of Radiology-ECR 2023, 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230226005049/en/
Contact information
Fernanda Fraga
Media Relations
ffraga@kaimaging.com
T: 226.215.9897
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DATA AI for Insurance Converts Complex Workflows into Governed, Repeatable AI-delivered Services5.8.2026 15:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced NTT DATA AI for Insurance, an AI-native agentic solution that converts complex core insurance workflows into governed, repeatable services. Built for highly regulated insurance environments, the Service-as-Software solution combines configurable AI agents, insurance-specific data models, workflow orchestration and enterprise-grade governance to maintain auditability, regulatory guardrails and human oversight. NTT DATA AI for Insurance helps carriers modernize underwriting, claims, customer service and other core insurance workflows while improving productivity across the enterprise. Powered by NTT DATA AIVista, the company's AI-native product platform, the solution combines a prebuilt insurance foundation with flexible configuration and targeted customization, enabling rapid deployment while adapting to each carrier's products, processes, operating model and regulatory requirements. The solution
‘Cheers to Beer’ Celebrates the Drink at the Heart of Life’s Meaningful Moments5.8.2026 15:00:00 EEST | Press release
Ahead of International Beer Day on August 7th, AB InBev, the world's leading brewer, launched “Cheers to Beer,” a new global campaign celebrating the timeless role beer plays in culture and communities around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805206698/en/ The campaign is anchored by a new film, created in partnership with Wieden+Kennedy, that celebrates the many moments of cheers that beer creates across geographies and generations. The film, which will be amplified globally, reinforces beer's role in life’s meaningful moments, big and small. “Beer is universal and woven into cultures and communities around the world,” said Michel Doukeris, CEO, AB InBev. “No matter who you are, what you do for a living, or where you live, when someone says, ‘Let’s grab a beer,’ you know it means something more. It’s an invitation to celebrate or to simply connect.” Beer’s enduring relevance is reinforced by a new
Tecnotree saavutti kaksinumeroisen tuloskasvun ja vauhditti toimituksia vuoden 2026 ensimmäisellä puoliskolla5.8.2026 14:04:00 EEST | Tiedote
Tecnotree, maailmanlaajuinen tekoälynatiivien digitaalisten liiketoiminnan tukijärjestelmien (BSS) ja televiestintäalan digitaalisten alustaratkaisujen toimittaja, julkisti vuoden 2026 ensimmäisen vuosipuoliskon taloudellisen tuloksensa. Yhtiö saavutti kasvua kaikissa keskeisissä taloudellisissa tunnusluvuissaan, paransi liikevoittomarginaaliaan 800 peruspisteellä ja eteni ennätyksellisen tilauskantansa toimittamisessa ripeästi. Pohjois-Amerikassa, Afrikassa ja Lähi-idässä toteutettiin yhteensä kahdeksan tuotantoonvientiä. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20260805483151/fi/ Tecnotree Delivers Double-Digit Profit Growth and Accelerated Deployment Momentum in H1 2026 Ensimmäinen vuosipuolisko (tammi–kesäkuu 2026) Liikevaihto oli 36,8 miljoonaa euroa (34,2 miljoonaa euroa), mikä merkitsee 7,5 prosentin kasvua edellisvuodesta. Vertailukelpoisin valuuttakurssein liikevaihto oli 37,6 miljoonaa euroa, jossa kasvua ol
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights5.8.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the second quarter and first half 2026 financial results and business highlights. “The first half of 2026 marked a defining period for Compass as we continued to build momentum across clinical, regulatory and commercial fronts in preparation for the potential approval and launch of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “Over the past six months, we have strengthened – and further validated – the consistent evidence supporting COMP360’s transformative potential, expanded our commercial readiness capabilities, deepened engagement across the treatment ecosystem, and advanced our rolling submission in support of a regulatory filing in Q4. Our focus now is on disciplined execution - completing our filing activities and ensuring we are ready to deliver COMP360 to patients with TRD as quickly as possib
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates5.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong second-quarter results underscore our continued growth as a global oncology leader. Our foundational hematology franchise, led by BRUKINSA, continues to gain momentum as we advance one of the industry’s deepest and most diverse pipelines. With differentiated capabilities spanning drug discovery, clinical development, manufacturing, and commercialization, we are well positioned for our next phase of global growth.” (Amounts in thousands of U.S. dollars and unaudited) Three Months Ended Six Months Ended June 30, June 30, 2026 2025 % Change 2026 2025 % Change Net product revenues $ 1,679,794 $ 1,302,076 29 % $ 3,167,123 $ 2,410,606 31 % Other revenue $ 25,277 $ 13,224 91 % $ 51,386 $ 21,973 134 % Total revenue $ 1,705,071 $ 1,315,300 30 % $ 3
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom